Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin | Zendy

G Penno | Zendy; Russo Russo | Zendy; Stefano Del Prato | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin

Author(s) -

G Penno,

Russo Russo,

Stefano Del Prato

Publication year - 2013

Publication title -

diabetes metabolic syndrome and obesity

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.853

H-Index - 43

ISSN - 1178-7007

DOI - 10.2147/dmso.s28951

Subject(s) - vildagliptin , medicine , linagliptin , glycemic , tolerability , hypoglycemia , renal function , diabetes mellitus , dipeptidyl peptidase 4 , glycated hemoglobin , type 2 diabetes , dipeptidyl peptidase 4 inhibitor , kidney disease , urology , endocrinology , adverse effect

Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel classified oral anti-diabetic drugs for the treatment of type 2 diabetes mellitus (T2DM) that provide important reduction in glycated hemoglobin, with a low risk for hypoglycemia and no weight gain. In T2DM patients with reduced renal function, adequate glycemic control is essential to delay the progress of kidney dysfunction, but they are at a greater risk of experiencing hypoglycemic events, especially with longer-acting sulfonylureas and meglitinides.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research